FGF23 and PTH Reshape How Doctors Understand Phosphate Disorders

Phosphorus underpins cellular energy (ATP), nucleic acid structure, and skeletal mineralization, yet its dysregulation is clinically underappreciated outside nephrology and metabolic bone disease. This chapter from the continuously updated, open-access Endotext resource offers a scholarly synthesis of primary phosphate metabolism disorders, written by an expert in pediatric endocrinology and orthopedics at Yale University School of Medicine.

The review focuses on how inorganic phosphate (PO4) is tightly regulated through intestinal and renal transport systems. Two master hormonal regulators take center stage: parathyroid hormone (PTH), long recognized for its phosphaturic effects, and Fibroblast Growth Factor 23 (FGF23), a bone-derived hormone whose discovery transformed understanding of phosphate diseases. Alpha-klotho, a co-receptor expressed predominantly in the kidney, confers tissue specificity for FGF23 signaling, making the kidney the principal organ of phosphate homeostasis.

The chapter catalogs clinical disorders arising from dysregulated phosphate handling—including X-linked hypophosphatemia, autosomal dominant and recessive hypophosphatemic rickets, tumor-induced osteomalacia, and hyperphosphatemic conditions. For each, the pathophysiologic role of FGF23 excess or deficiency is delineated, enabling more precise diagnosis and treatment targeting.

For longevity medicine, the implications extend beyond rare bone diseases. Phosphate excess, particularly in chronic kidney disease, promotes vascular and soft-tissue calcification (heterotopic mineralization) and correlates strongly with cardiovascular mortality. Even in non-CKD populations, elevated phosphate within the normal range has been associated with adverse cardiovascular outcomes, suggesting phosphate as a modifiable aging-related risk factor.

As a book chapter rather than an original clinical trial, evidence hierarchies differ from primary research. Nonetheless, it synthesizes decades of mechanistic and clinical data and highlights emerging FGF23-targeted biologics (e.g., burosumab) as paradigm-shifting treatments, with implications for how phosphate dysregulation might be addressed across the lifespan.